长期以来的临床实践已经证明,无论存在BRAF突变与否,抗CTLA-4和抗PD-1治疗都能比较好的控制黑色素瘤患者的病情进展,但是有关疗效评估和预后评价方面的指标一直是学界研究和争论的重点。之前关于BRAF抑制剂的研究已经证明,年龄越大的黑色素瘤患者,其发生治疗抵抗的风险也就越大[1],而关于老年非小细胞肺癌患者使用PD-...
Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?CTLA-4PD-L1PD-1Immune checkpoint inhibitor therapiesImmunotherapiesBiomarkersNeoantigensAlthough durable clinical responses are achieved in a significant number of patients given ...
However, the negative results of the phase III clinical trial of the would-be first-in-class IDO1 inhibitor (epacadostat) in combination with an anti-PD1 antibody (pembrolizumab) in patients with advanced malignant melanoma call for a better understanding of the role of IDO1 inhibition. In ...
examined. Our results demonstrated that NPD1 is a highly potent endogenous inhibitor of TRPV1 (IC50_0.4 nM). NPD1 blocked both TRPV1 and TNF-_-mediated spinal cord synaptic transmission and long-term potentiation (LTP). In addition, spinal adm NPD1的角色在调控突触神经的传输和痛苦有被审查...
With the worldwide trend of aging populations, the number of older adults who develop and survive cancer is likely to increase. In the last decade, oncology drug development has shifted away from conventional chemotherapeutics towards agents that can ‘target’ a driver mutation of a specific cance...
and several studies have shown that the gut microbiome has an effect on the response to checkpoint inhibitor immunotherapies11,12for example improved efficacy of anti-PD1 treatment, with increased antitumor T cell responses, was seen i...
T-VEC is currently being evaluated as a potential treatment in melanoma and other advanced cancers [19, 20]. In a pre-clinical study in breast cancer bearing mice, the combination of an anti-PD1 antibody and a multi-peptide vaccine prolonged the vaccine-induced progression-free survival (PFS)...
Their phenotype is now characterized by the increased expression of specific markers, including PD1, TIM-3 (h). Furthermore, a change in NF-kB composition occurs. In particular, its pro-inflammatory heterodimer (including the components p65 and p50) is replaced by an anti-inflammatory homodimer ...
Mutations in KRAS are often associated with an increase in the expression of PD-L1 on tumor cells and with a good response to treatment with anti-PD1/anti-PD-L1 medication [202,203,204]. Therefore, in the case of first-line treatment, a therapeutic strategy targeting KRASG12C can be res...
Glioblastoma multiforme (GBM) is a primary brain tumor that is very aggressive, resistant to treatment, and characterized by a high degree of anaplasia and proliferation. Routine treatment includes ablative surgery, chemotherapy, and radiotherapy. However, GMB rapidly relapses and develops radioresistance...